Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial

European Heart Journal

Volumn 34, Issue 31, 2013, Pages 2453-2463

  Pitt, Bertram ^a   Kober, Lars ^b   Ponikowski, Piotr ^c   Gheorghiade, Mihai ^d   Filippatos, Gerasimos ^e   Krum, Henry ^f   Nowack, Christina ^g   Kolkhof, Peter ^g   Kim, So Young ^h   Zannad, Faiez ⁱ  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^f MONASH UNIVERSITY   (Australia)

^g BAYER PHARMA AG   (Germany)

^h BAYER AG   (Germany)

ⁱ UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Aldosterone; Antagonist; Chronic kidney disease; Heart failure; Mineralocorticoid receptor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BAY 948862; BRAIN NATRIURETIC PEPTIDE; MINERALOCORTICOID ANTAGONIST; PLACEBO; POTASSIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG;

AGED; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE; ANTAGONIST; CHRONIC KIDNEY DISEASE; HEART FAILURE; MINERALOCORTICOID RECEPTOR;

ADMINISTRATION, ORAL; AGED; ALBUMINURIA; ALDOSTERONE; BLOOD PRESSURE; CARDIO-RENAL SYNDROME; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POTASSIUM;

EID: 84882415231     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht187     Document Type: Article

References (17)

1. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
3. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33: 1787-1847.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, YancyCW. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
5. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, Nitsche A, Erguden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012;7: 1385-1403.
6. Delbeck M, Kretschmer A, Kast R, Bärfacker L, Hartmann E, Schaefer S, Kolkhof P. Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure. Eur Heart J 2012;33(Abstract Supplement):772-773.
7. Kolkhof P, Kretschmer A, Baerfacker L, Hartmann E, Schaefer S. Improved survival and nephroprotection in hypertensive rats by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist. Eur Heart J 2012;33(Abstract Supplement): 978-979.
8. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F. Rationale and design of ARTS: a randomized, doubleblind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012;14:668-675.
9. Pitt B, Anker SD, Bushinsky DA, KitzmanDW, Zannad F, Huang IZ. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32:820-828.
10. Mak G, Murphy NF, Ali A, Walsh A, O'Loughlin C, Conlon C, McCaffrey D, LedwidgeM, McDonald K. Multiple neurohumoral modulating agents in systolic dysfunction heart failure: arewe lowering blood pressure too much J Card Fail 2008;14: 555-560.
11. Pitt B. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much Curr Heart Fail Rep 2009;6:112-116.
12. Nishizaka MK, Zaman MA, CalhounDA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-930.
13. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012;350:310-317.
14. Albrecht-Küpper B, Kretschmer A, Kast R, Baerfacker L, Schaefer S, Kolkhof P. Pronounced cardiac protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical rat model of heart failure. Eur Heart J 2012; 33(Abstract Supplement):7.
15. Lentini S, Kimmeskamp-Kirschbaum N,Wensing G, Heinig R. BAY 94-8862 exerts a potent natriuretic effect in healthy male subjects pre-treated with fludrocortisone: findings from a proof-of-concept study. Circulation 2012;126:A10732.
16. Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010;12: 617-622.
17. Pitt B, RemmeW, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-1321.